Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AMG 655 · 4 trials · 14 indications
| Arm | Type | Description |
|---|---|---|
| Cohort 4 | EXPERIMENTAL | AMG 655 (intermediate dose) with Vorinostat |
| Cohort 1 | EXPERIMENTAL | AMG 655 (low dose) with Bortezomib |
| Cohort 2 | EXPERIMENTAL | AMG 655 (low dose) with vorinostat |
| Cohort 5 | EXPERIMENTAL | AMG 655 (high dose) with Bortezomib |
| Cohort 6 | EXPERIMENTAL | AMG 655 (high dose) with Vorinostat |
| Cohort 7 | EXPERIMENTAL | Part 2 - Mantle Cell Lymphoma subjects only: AMG 655 at dose TBD with Bortezomib |
| Cohort 3 | EXPERIMENTAL | AMG 655 (intermediate dose) with Bortezomib |
| Arm 2 | EXPERIMENTAL | Low Dose AMG 655 with paclitaxel/carboplatin |
| Arm 3 | PLACEBO_COMPARATOR | Placebo with paclitaxel/carboplatin |
| Arm 1 | EXPERIMENTAL | AMG 655 High doseplus paclitaxel/carboplatin |
| AMG 655 Low Dose | EXPERIMENTAL | AMG 655 (low dose) + mFOLFOX6 + Bevacizumab |
| Placebo | PLACEBO_COMPARATOR | Placebo + mFOLFOX6 + Bevacizumab |
| AMG 655 High Dose | EXPERIMENTAL | AMG 655 (high dose) + mFOLFOX6 + Bevacizumab |
| Name | Type | Description |
|---|---|---|
| AMG 655 | DRUG | AMG 655 is an investigational, fully human monoclonal agonist antibidy that selectively binds to Death Receptor-5 (DR-5). |
| Vorinostat | OTHER | Vorinostat, a second generation polarplanar compound, binds to the catalytic domain of the histone deacetylases (HDAC). |
| Bortezomib | OTHER | A dipeptide boronic acid analogue with antineoplastic activity. |
| AMG 655 placebo | OTHER | Inactive dummy AMG 655 (to maintain blind) |
| Placebo | OTHER | Inactive dummy AMG 655 (to maintain blind) |
| Doxorubicin | DRUG | Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of Daunorubicin. |
| Modified FOLFOX6 | DRUG | Combination treatment comprising oxaliplatin (85 mg/m2), leucovorin (400 mg/m2) and bolus 5-FU (400 mg/m2) and continuous IV 5-FU (2400 mg/m2)\] administered by intravenous infusion once every 14 days (+3 days) |
| Bevacizumab | DRUG | Bevacizumab will be administered at a dose of 5 mg/kg by intravenous infusion on day 1 of each 14 day cycle (+3 days). |
Inclusion Criteria: * Part 1: Subjects must have a pathologically confirmed diagnosis of lymphoma that is relapsed or refractory to standard treatment or for which no curative therapy is available. Lymphoma subtypes that are eligible for enrollment include low grade lymphoma, mantle cell lymphoma, ...
AMG 655 is an investigational oncology drug being studied for the treatment of Hodgkin's lymphoma, metastatic colorectal cancer, locally advanced or metastatic unresectable soft tissue sarcoma, and non-small cell lung cancer. It is being developed by Amgen Inc. and is currently in Phase 1 clinical trials.
AMG 655 is a small molecule being developed by Amgen Inc. for oncology indications. Its specific molecular target has not been disclosed in the available clinical trial information. The drug is being studied in combination with other agents for various cancer types.
AMG 655 is being developed by Amgen Inc., a biopharmaceutical company traded on NASDAQ under the ticker AMGN. The drug is currently in Phase 1 clinical development for multiple oncology indications, including non-small cell lung cancer and metastatic colorectal cancer.
AMG 655 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials have been completed for its use in non-small cell lung cancer, metastatic colorectal cancer, soft tissue sarcoma, and lymphoma.
AMG 655 has been studied in several completed Phase 1 clinical trials. These include NCT00534027 for non-small cell lung cancer, NCT00625651 for metastatic colorectal cancer, NCT00626704 for soft tissue sarcoma, and NCT00791011 for lymphoma. The trials enrolled a total of 202 participants.
AMG 655 is also known by its development code AMG 655. No other alternative names have been established for this drug in the available clinical trial information. It is being developed by Amgen Inc. for various oncology indications.